Cell and Gene Therapy Catapult brings together over 20 organisations with the aim to accelerate technology development and potentially lower cost in cell and gene therapy manufacturing
The consortium will assess multiple process analytical technologies (PAT) which are either new or routinely used in other industries
Released: 8th June, 2021
A consortium of over 20 organisations has been formed today by the Cell and Gene Therapy Catapult, comprising of pharmaceutical companies, technology providers, therapy developers and charities. The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry.
This consortium is the first of this scale, functional expertise and mission within the cell and gene therapy space, bringing together multiple industries to develop cell and gene therapy specific process analytical technologies. Development of industry specific PAT is fundamental to enable monitoring and control during the manufacturing process: reducing batch failures and manufacturing costs, allowing for accelerated progress towards commercialisation in this space.
Through this model of collaborative work, sharing of data from the research carried out, partners will accelerate their expertise in this area and gain industry specific knowledge to integrate and combine cell and gene therapy process analytical technologies into their offering. This PAT consortium will act as a catalyst in accelerating the development of the necessary knowledge and understanding at reduced cost and investment risk to each organisation.
Access to this knowledge will allow technology providers and manufacturers to develop lower cost and more robust manufacturing processes, accelerating development of advanced therapeutics.
Matthew Durdy, Chief Executive Officer at Cell Gene Therapy Catapult commented:
Nicholas Medcalf, Deputy Challenge Director – Medicines Manufacturing for Innovate UK said:
The organisations that have formed the process analytics consortium are: ABER Instruments; Anthony Nolan; BD, Bio-Techne; Cambridge Consultants; Cell and Gene Therapy Catapult; ChemoMetec; C-CIT Sensors; Cytiva; Eppendorf; GlaxoSmithKline (GSK); HORIBA; IMSPEX Diagnostics Ltd; Kaiser Optical Systems, an Endress+Hauser company; Lonza; Ocean Insight; Ori Biotech; Oxford Nanoimaging; Quantex; See-Through; TeloNostiX; Terumo Blood and Cell Technologies; Univercells Technologies.
Released: 8th June, 2021